Aspen to distribute Merck products
Effective immediately, Aspen is taking over the sales, distribution and marketing of a portfolio of dermatology products from Merck, with estimated annual sales of $50 million.
Effective immediately, Aspen is taking over the sales, distribution and marketing of a portfolio of dermatology products from Merck, with estimated annual sales of $50 million.
This licensing deal takes Aspen gross annualized sales in Australia and New Zealand to around $230 million, excluding Asia and the proposed Sigma transaction.
The products involved are:
- Antroquoril
- Celestone
- Diprosone
- Eleuphrat
- Elocon
- Novasone
- Propecia
Please be assured of our ongoing commitment to good customer service and a seamless process, however, should you have any queries, please feel free to contact Aspen at any time.
Content Last Reviewed On July 16, 2018